PRECIDENTD (Type 2 Diabetes) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to learn more about how 2 different classes of diabetes medications help lower the risk of heart disease. The types of diabetes medications that have been shown to reduce the risk of new or worsening heart disease are SGLT2 inhibitors and GLP-1 receptor agonists. We don't know which of these drugs might be preferable to reduce heart disease risk for diabetes patients, and we hope this study can help us find out which drug(s) may be the most appropriate for most patients.
Diabetes tipo 2
¿Quién puede participar en el Estudio?
Adults with type 2 diabetes who:
- Are ages 40+ and have had a heart attack, or a stroke, or have had stents placed to open their blood vessels; OR
- Are ages 60+ and have hemoglobin AIC above 8, or have chronic kidney disease, or who smoke
For more information about this study, contact the study team at chad.harrell@duke.edu.
¿Qué Implica?
Si decide unirse a este estudio, recibirá una asignación aleatoria (como lanzar una moneda al aire) para:
- Take an SGLT2 inhibitor; OR
- Take a GLP-1 receptor agonist
SGLT2 inhibitors include the following medications: Jardiance®, Farxiga®, and Invokana®.
GLP-1 receptor agonists include the following medications: Victoza®, Trulicity®, Ozempic®, and Rybelsus®.
All drugs that are used in this study are FDA-approved for the treatment of type 2 diabetes.
Detalles del Estudio
